Related Experiment Video

Updated: Feb 2, 2026

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.8K

Introduction of novel agents in the treatment of primary CNS lymphoma

Christian Grommes1, Lakshmi Nayak2, Han W Tun3

  • 1Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York.

Neuro-Oncology
|November 14, 2018
PubMed

Insights

Novel treatments for primary central nervous system lymphoma (PCNSL) target key pathways. Clinical trials show promising response rates for recurrent or refractory PCNSL using novel agents like BTK inhibitors and IMiDs.

Area of Science:

  • Oncology
  • Immunology
  • Neurology

Background:

  • Primary central nervous system lymphoma (PCNSL) pathogenesis involves B-cell receptor and Toll-like receptor pathways.
  • Immune evasion and a suppressed tumor immune microenvironment are critical in PCNSL development.

Purpose of the Study:

  • To provide an overview of recent advancements in PCNSL treatment.
  • To summarize clinical trial results for novel agents in recurrent or refractory PCNSL.

Main Methods:

  • Review of recent clinical trials and literature on PCNSL.
  • Focus on novel agents targeting aberrant pathways in PCNSL.

Main Results:

  • Agents like Bruton tyrosine kinase (BTK) inhibitors (e.g., ibrutinib) and immunomodulatory drugs (IMiDs) show high response rates in salvage settings.
  • Clinical trials are evaluating immune checkpoint inhibitors, IMiDs, BTK, phosphatidylinositol-3 kinase, and mammalian target of rapamycin inhibitors.

Conclusions:

  • Novel agents targeting specific molecular pathways offer promising therapeutic strategies for PCNSL.
  • Further research and clinical trials are essential for optimizing treatment for recurrent or refractory PCNSL.
Keywords:
BTKIMiDPCNSLimmune checkpoint inhibitiontargeted agents

More Related Videos

Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models07:12

Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models

Published on: July 7, 2016

21.0K
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

20.5K

Related Concept Videos

CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
806
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.6K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
538
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
553
CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1.3K
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.4K